as 07-08-2024 4:00pm EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Founded: | 2018 | Country: | Germany |
Employees: | N/A | City: | BERLIN |
Market Cap: | 221.0M | IPO Year: | 2021 |
Target Price: | $12.00 | AVG Volume (30 days): | 820.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.24 | EPS Growth: | N/A |
52 Week Low/High: | $1.02 - $2.85 | Next Earning Date: | 08-08-2024 |
Revenue: | $277,000 | Revenue Growth: | 2.97% |
Revenue Growth (this year): | -2.55% | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Rao Srinivas | ATAI | See Remarks | Apr 2 '24 | Sell | $1.85 | 61,640 | $114,034.00 | 113,360 | SEC Form 4 |
Johnson Anne Nagengast | ATAI | Chief Financial Officer | Apr 2 '24 | Sell | $1.85 | 27,410 | $50,708.50 | 73,590 | SEC Form 4 |
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
GlobeNewswire
18 days ago
GOBankingRates
a month ago
AFP
a month ago
AFP
a month ago
AFP
a month ago
Business Insider
a month ago
Insider Monkey
a month ago
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.